Aarti Pharmalabs Limited · NSE:AARTIPHARM
Aarti Pharmalabs — Q1 FY2026 Earnings Presentation
28 slides from Aarti Pharmalabs's earnings presentation, Aug 13, 2025
Slide 1: Cover letter to stock exchanges: Results Presentation
August 13, 2025 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE LTD. National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, “Exchange Plaza”, Plot No. C/1, Mumbai - 400 001 G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 SCRIP CODE: 54
Slide 2: Investor Presentation August 2025
INVESTOR PRESENTATION August 2025
Slide 3: Snapshot
SNAPSHOT 25 Years of Pharmaceutical Excellence 220+ Products 500+ Global Clients State-of-the-art 3 R&D facilities 60 Patents Filed 50+ Export Countries Manufacturing 6 Units 53 US DMF 2,200+ Employees 3 USFDA Units 35 CEP Global 15-20% Market Share 0.19x Net Debt/Equity AA- Credit rating in Xanthin
Slide 4: Company Overview
1 COMPANY OVERVIEW 2 BUSINESS OVERVIEW 3 STRATEGIC OVERVIEW 4 FINANCIAL OVERVIEW Aarti Pharmalabs Limited
Slide 5: Company Overview
COMPANY OVERVIEW STANDALONE REVENUE (INR Mn) • Aarti Pharmalabs Limited (APL) is part of the Aarti group – a diversified chemical conglomerate with & EBITDA MARGINS (%) group turnover of INR 130+ bn (FY25) 17,714 • Globally recognized manufacturer of generic API, Xanthine derivatives and a leading p
Slide 6: Key Milestones
KEY MILESTONES • 2024 Started 21 MW solar power project at Akola, Maharashtra • Expansion of semi-commercial production block at Vapi 2022 • Expanded block for CSD in Vapi and API in Tarapur units • Acquired land at Atali for future growth 12 • Successfully demerged the pharmaceutical business of Aa
Slide 7: Geographical Presence
GEOGRAPHICAL PRESENCE Atali Vapi - Unit II Tarapur - Unit III, IV, V, VI Dombivli - Unit I Gujarat Mumbai Maharashtra LOCATION MANUFACTURING UNITS CERTIFICATIONS & AUDIT DATE Dombivali Unit - I (API, Intermediates, CDMO) USFDA - Jun 2022 Unit - II (API, Intermediates, CDMO) Vapi USFDA - Sep 2009, Au
Slide 8: Manufacturing Capabilities
MANUFACTURING CAPABILITIES END TO END CAPABILITIES UNDER ONE UMBRELLA Hydrogenation facilities from lab-scale to 25 years of experience in pharmaceuticals manufacturing scale (0.1-10 KL reactors) manufacturing for global clients Impeccable regulatory track record and facilities Cryogenic reactors op
Slide 9: Research & Development
RESEARCH & DEVELOPMENT 3 40+70+ 3 State of the art Products developed and R&D Centers at manufactured on kilo-lab Maharashtra & Gujarat scale in FY25 25+ 5% 70+ 3 18 3 New products R&D Spend (as a PhDs launched at plant scale percent of API+Int & in FY25 CDMO sales ) in FY25 108 3 42 Cr70+ 3 60 70+
Slide 10: Business Overview
1 COMPANY OVERVIEW 2 BUSINESS OVERVIEW 3 STRATEGIC OVERVIEW 4 FINANCIAL OVERVIEW Aarti Pharmalabs Limited
Slide 11: Key Business Segments
KEY BUSINESS SEGMENTS QUARTERLY REVENUE BREAK-UP 43.5% 53.6% 49.6% Xanthine Derivatives & Allied Products API & Intermediates 43.6% 40.8% 43.9% CDMO/CMO 12.9% 9.6% 2.4% FY25 Q1-FY25 Q1-FY26 CDMO/CMO API & Intermediates Xanthine derivatives
Slide 12: Xanthine Derivatives & Allied Products
XANTHINE DERIVATIVES & ALLIED PRODUCTS • Largest Indian manufacturer of Xanthine Derivatives, including Caffeine (largest capacity in India), SALES QUANTITY SPLIT (Q1-FY26) Theophylline Anhydrous, Aminophylline, Etophylline, and Theophylline • Non-Chinese dependent and fully backward integrated manu
Slide 13: API & Intermediates
API & INTERMEDIATES • Specialized player in the development and manufacturing of HPAPIs, catering to the demand for critical drugs used in oncology, corticosteroids, and cytotoxic medicines. MARKET SEGMENTATION (Q1-FY26) • Backward integrated for most APIs, with control over entire production value
Slide 14: CDMO & CMO
CDMO & CMO • Amongst leading small molecule CDMO/CMO players in India, working with big pharma, innovators CDMO Sales (INR Cr) and biotech companies. • Offering end to end services including process development and manufacturing of KSMs, RSMs, Intermediates & GMP APIs for small molecule NCEs, from e
Slide 15: Strategic Overview
1 COMPANY OVERVIEW 2 BUSINESS OVERVIEW 3 STRATEGIC OVERVIEW 4 FINANCIAL OVERVIEW Aarti Pharmalabs Limited
Slide 16: Capital Expenditure Outlook
CAPITAL EXPENDITURE OUTLOOK Greenfield Capex – Atali Project (Gujarat) Brownfield Capex – Tarapur (Maharashtra) Estimated Investment INR 400 crores Estimated Investment INR 150 crores Capacity ~450 KL (Phase 1) Installed Capacity 9,000 MTPA Land Acquired 80 acres Current Utilization Almost 100% Mech
Slide 17: Future Outlook
FUTURE OUTLOOK FY25 FY26E Growth Drivers No. of 6 7 Strong pipeline of new products in API & Intermediates business Sites Reactor 1100+kL 1500+kL Greenfield Atali Site to boost Intermediates and CDMO/CMO business Capacity* CDMO 208 Cr 30 - 40% Growth Expand on-ground global sales presence in the USA
Slide 18: Financial Overview
1 COMPANY OVERVIEW 2 BUSINESS OVERVIEW 3 STRATEGIC OVERVIEW 4 FINANCIAL OVERVIEW Aarti Pharmalabs Limited
Slide 19: Quarterly Consolidated Income Statement
QUARTERLY CONSOLIDATED INCOME STATEMENT PARTICULARS (INR Mn) Q1-FY26* Q4-FY25 Q-o-Q Q1-FY25 Y-O-Y Operational Revenue 3,862 5,638 (31.5)% 5,555 (30.5)% Operating Expenses 2,909 4,182 (30.4)% 4,590 (36.6)% EBITDA 953 1,456 (34.5)% 965 (1.2)% EBITDA Margin (%) 24.68% 25.82% (114) Bps 17.37% 731 Bps De
Slide 20: Annual Consolidated Income Statement
ANNUAL CONSOLIDATED INCOME STATEMENT PARTICULARS (INR Mn) Q1-FY26* FY25 FY24 Operational Revenue 3,862 21,151 18,526 Operating Expenses 2,909 16,507 14,666 EBITDA 953 4,644 3,860 EBITDA Margin (%) 24.68% 21.96% 20.84% Depreciation and Amortisation 228 869 732 Finance costs 68 269 172 Other Income 16
Slide 21: Quarterly Standalone Income Statement
QUARTERLY STANDALONE INCOME STATEMENT PARTICULARS (INR Mn) Q1-FY26 Q4-FY25 Q-o-Q Q1-FY25 Y-O-Y Operational Revenue 3,753 5,296 (29.1)% 3,935 (4.6)% Operating Expenses 2,801 3,865 (27.5)% 3,099 (9.6)% EBITDA 952 1,431 (33.5)% 836 13.9% EBITDA Margin (%) 25.37% 27.02% (165) Bps 21.25% 412 Bps Deprecia
Slide 22: Annual Standalone Income Statement
ANNUAL STANDALONE INCOME STATEMENT PARTICULARS (INR Mn) Q1-FY26 FY25 FY24 Operational Revenue 3,753 17,714 15,021 Operating Expenses 2,801 13,449 11,560 EBITDA 952 4,265 3,461 EBITDA Margin (%) 25.37% 24.08% 23.04% Depreciation and Amortisation 228 791 660 Finance costs 68 256 166 Other Income 16 14
Slide 23: Historical Consolidated Balance Sheet
HISTORICAL CONSOLIDATED BALANCE SHEET ASSETS (INR Mn) FY23 FY24 FY25 EQUITY & LIABILITIES (INR Mn) FY23 FY24 FY25 Non-current assets Equity share capital 453 453 453 Property, plant and equipment 9,227 9,942 10,887 Equity Share Capital Pending allotment - Capital work-in-progress 622 785 3,066 Right
Slide 24: Historical Standalone Balance Sheet
HISTORICAL STANDALONE BALANCE SHEET ASSETS (INR Mn) FY23 FY24 FY25 EQUITY & LIABILITIES (INR Mn) FY23 FY24 FY25 Assets Equity & Liabilities Non-current assets Equity share capital 453 453 453 Property, plant and equipment 8,471 9,160 10,135 Equity Share Capital Pending allotment - - - Capital work-i
Slide 25: Consolidated Financial Highlights
CONSOLIDATED FINANCIAL HIGHLIGHTS OPERATIONAL INCOME (INR Mn) EBITDA (INR Mn) & EBITDA MARGINS PAT (INR Mn) & PAT MARGINS (%) (%) 21,151 19,452 4,644 18,526 2,724 3,860 3,421 2,169 1,935 24.68% 953 12.82% 20.84% 21.96% 3,862 17.59% 11.71% 12.88% 495 9.95% FY23 FY24 FY25 Q1-FY26* FY23 FY24 FY25 Q1-FY
Slide 26: Capital Market Information
CAPITAL MARKET INFORMATION SHARE PRICE UP TO 30th June, 2025 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% -10.0% -20.0% Jul-24 Aug-24 Sep-24 Oct-24 Nov-24 Dec-24 Jan-25 Feb-25 Mar-25 Apr-25 May-25 Jun-25 Aarti Sensex PRICE DATA (AS ON 30th June 2025) INR SHAREHOLDING PATTERN (AS ON 30th June, 2025) DII,
Slide 27: Disclaimer
DISCLAIMER Aarti Pharmalabs Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all event
Slide 28: Thank You
THANK YOU AARTI PHARMALABS LIMITED